Aurinia Presentation Details
Date: Tuesday, Feb 2nd, 2016
Time: 10:25 a.m. Eastern
Location: New York Omni Berkshire Place Hotel
About Aurinia
Aurinia is a clinical stage pharmaceutical company focused on the global nephrology market. It is currently collecting data in its 265 patient Phase 2b clinical trial to evaluate the efficacy of its drug, voclosporin, as a treatment for LN. LN is an inflammation of the kidneys, that if inadequately treated can lead to end-stage renal disease, making LN a serious and potentially life-threatening condition.
Voclosporin is a novel and potentially best-in-class calcineurin inhibitor ("CNI") with extensive clinical data in over 2,000 patients in other indications. Voclosporin is made by a modification of a single amino acid of the cyclosporine molecule (a CNI approved for use in transplant patients since 1983). This modification results in a more predictable pharmacokinetic and pharmacodynamic relationship, an increase in potency vs. cyclosporine, an altered metabolic profile, and potential for flat dosing.
Visit www.auriniapharma.com for more information.
Mr. Michael Martin Chief Operating Officer Aurinia Pharmaceuticals Inc. (250) 708-4272 (250) 744-2498 (fax) mmartin@auriniapharma.com | Mr. Stephen W. Zaruby Chief Executive Officer Aurinia Pharmaceuticals Inc. (250) 708-4293 (250) 744-2498 (fax) szaruby@auriniapharma.com |
Renmark Financial Communications Inc. Barry Mire: bmire@renmarkfinancial.comLaura Welsh: lwelsh@renmarkfinancial.com Tel: (416) 644-2020 or (514) 939-3989 |
Aurinia Pharmaceuticals Inc. issued this content on 29 January 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 30 January 2016 00:06:01 UTC
Original Document: http://www.auriniapharma.com/dnn/LinkClick.aspx?fileticket=YbU4gJ_ikKo=&tabid=63&mid=653